Management of viral hepatitis B

@article{Pramoolsinsup2002ManagementOV,
  title={Management of viral hepatitis B},
  author={Chutima Pramoolsinsup},
  journal={Journal of Gastroenterology and Hepatology},
  year={2002},
  volume={17}
}
  • Chutima Pramoolsinsup
  • Published 1 February 2002
  • Biology, Medicine
  • Journal of Gastroenterology and Hepatology
Hepatitis B virus (HBV) infection is a major global health concern and is the most common cause of chronic liver disease worldwide. The natural history and clinical outcomes of chronic HBV infection are determined by the viral replication cycle and the host immune responses. Treatment of chronic hepatitis B is directed at interrupting the natural history by suppressing HBV replication before development of any significant irreversible liver cell damage. Effective antiviral therapies should be… 
Hepatitis C Virus; Its Eradication from the Serum is Just Possible
TLDR
Cupping therapy constitutes a therapeutic revolution in hepatitis C viral illness treatment through massive eradication of the virus from the serum in a rapid immediate onset after the cupping session.
Innate immune responses in hepatitis B virus (HBV) infection
TLDR
The current understanding of innate immunity inHBV infection is presented and of the challenges associated with clearing of the HBV infection are presented.
Cytokine-Mediated Immunopathogenesis of Hepatitis B Virus Infections
TLDR
Recent advances on the roles of various cytokines in different phases ofHBV infection and cytokine-related mechanisms for impaired viral control and liver damage during HBV infection are discussed, and experimental therapeutic applications of cytokines are focused on to gain a better understanding of this newly emerging aspect of disease pathogenesis.
Current and future therapy of chronic hepatitis
TLDR
This chapter focuses on current therapeutic options and novel strategies for the treatment of chronic hepatitis and autoimmune hepatitis, both of which are frequent conditions in the Western world.
HIV and hepatitis B: a review.
TLDR
It is not surprising that HBV and HIV coinfection is common with 6%–10% of HIV-positive individuals being coinfected with these viruses because of the common routes of transmission.
Hepatitis B viral load predicts survival of HCC patients undergoing systemic chemotherapy
TLDR
For HCC patients with HBV chronic infection/exposure, a high viral load prior to treatment is an adverse factor for survival and may be associated with a higher incidence of severe hepatitis during chemotherapy.
Global Epidemiology of Hepatitis B Virus
TLDR
HBV vaccination programs will decrease the future global burden of HBV infection and evidence of reduced burden is mounting in country-specific populations, but vaccination programs have still not been implemented in all countries, thereby maintaining reservoirs of infection and continued HBV transmission.
Role of Antivirus Therapy in Treatment of Hepatocellular Carcinoma with Chronic Hepatitis B Infection
TLDR
Antivirus therapy using lamivudine and Tα1 postoperatively may suppress the HBV reaction, delay the recurrent time and prolong the survival for HCC patients coexisting chronic HBV infection with active virus replication.
HEPATITIS AND PHYSIOLOGY OF LIVER CELLS-A REVIEW
TLDR
It is recommended that hepatitis screening should be incorporated in the routine antenatal check up, and government at all levels should be proactive in innovation and immediate implementation of a general child and adolescent immunization against HBV to prevent further spread of this virus.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 197 REFERENCES
Current therapeutic trends in therapy for chronic viral hepatitis
  • Y. Liaw
  • Medicine, Biology
    Journal of gastroenterology and hepatology
  • 1997
TLDR
Evidence to suggest that IFN therapy, when associated with response, tends to reduce the risk of cirrhosis or HCC and prolongs survival, and there is no doubt that satisfactory treatment of chronic viral infection will require more effective agents and demand optimal treatment strategies, many of which are yet to be found.
Treatment of chronic viral hepatitis.
Immunotherapy of chronic hepatitis B by anti HBV vaccine.
Natural history of chronic hepatitis B virus infection in adults with emphasis on the occurrence of cirrhosis and hepatocellular carcinoma
  • C. Chu
  • Medicine, Biology
    Journal of gastroenterology and hepatology
  • 2000
TLDR
The outcome of HBV‐infected persons with ‘spontaneous’ seroclearance of HBsAg is usually favourable, though progress to cirrhosis and HCC is still possible; the development of HCC, however, is closely related to the severity of the underlying liver disease.
Lamivudine therapy for chemotherapy-induced reactivation of hepatitis B virus infection
TLDR
Lamivudine therapy should be considered for the treatment of HBV reactivation and might play a future role as preemptive therapy of HBv reactivation in patients with prior hepatitis B or chronic hepatitis B with inactive viral replication.
Acute Exacerbation of Chronic Hepatitis B Virus Infection After Withdrawal of Lamivudine Therapy
TLDR
Hepatitis after withdrawal of lamivudine resembles acute hepatitis B with a predominance of anicteric flares within a time frame of 6 months, and active management of hepatitis flares following withdrawal of nucleoside analogue therapy should be investigated.
Lamivudine for chronic delta hepatitis
TLDR
Lamivudine is a potent inhibitor of HBV‐DNA replication, but does not improve disease activity or lower HDV‐RNA levels in patients with chronic delta hepatitis.
Multicenter study of lamivudine therapy for hepatitis B after liver transplantation
TLDR
Lamivudine is a potentially effective therapy for hepatitis B after liver transplantation and blinded histological assessments showed improvement in the histological activity index.
End‐stage liver disease and liver transplantation: Role of lamivudine therapy in patients with chronic hepatitis B
  • E. Keeffe
  • Medicine, Biology
    Journal of medical virology
  • 2000
TLDR
Lamivudine has a potential role for the treatment of patients with hepatitis B‐related end‐stage liver disease, for prophylaxis in patients undergoing liver transplantation, and in thetreatment of recurrent or de novo HBV infection after transplantation.
...
1
2
3
4
5
...